JP2018083821A5 - - Google Patents

Download PDF

Info

Publication number
JP2018083821A5
JP2018083821A5 JP2017245743A JP2017245743A JP2018083821A5 JP 2018083821 A5 JP2018083821 A5 JP 2018083821A5 JP 2017245743 A JP2017245743 A JP 2017245743A JP 2017245743 A JP2017245743 A JP 2017245743A JP 2018083821 A5 JP2018083821 A5 JP 2018083821A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid position
substitution
wild type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017245743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018083821A (ja
JP6592071B2 (ja
Filing date
Publication date
Priority claimed from US13/418,242 external-priority patent/US9175331B2/en
Application filed filed Critical
Publication of JP2018083821A publication Critical patent/JP2018083821A/ja
Publication of JP2018083821A5 publication Critical patent/JP2018083821A5/ja
Application granted granted Critical
Publication of JP6592071B2 publication Critical patent/JP6592071B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017245743A 2012-03-12 2017-12-22 ヒトezh2の阻害剤およびその使用方法 Active JP6592071B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/418,242 US9175331B2 (en) 2010-09-10 2012-03-12 Inhibitors of human EZH2, and methods of use thereof
US13/418,242 2012-03-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015500523A Division JP6321619B2 (ja) 2012-03-12 2013-03-12 ヒトezh2の阻害剤およびその使用方法

Publications (3)

Publication Number Publication Date
JP2018083821A JP2018083821A (ja) 2018-05-31
JP2018083821A5 true JP2018083821A5 (cg-RX-API-DMAC7.html) 2018-07-12
JP6592071B2 JP6592071B2 (ja) 2019-10-16

Family

ID=47913638

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015500523A Active JP6321619B2 (ja) 2012-03-12 2013-03-12 ヒトezh2の阻害剤およびその使用方法
JP2017245743A Active JP6592071B2 (ja) 2012-03-12 2017-12-22 ヒトezh2の阻害剤およびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015500523A Active JP6321619B2 (ja) 2012-03-12 2013-03-12 ヒトezh2の阻害剤およびその使用方法

Country Status (14)

Country Link
EP (2) EP3536314A1 (cg-RX-API-DMAC7.html)
JP (2) JP6321619B2 (cg-RX-API-DMAC7.html)
KR (4) KR102453519B1 (cg-RX-API-DMAC7.html)
CN (2) CN104540500B (cg-RX-API-DMAC7.html)
AU (4) AU2013232229B2 (cg-RX-API-DMAC7.html)
CA (2) CA3177515A1 (cg-RX-API-DMAC7.html)
DK (1) DK2825161T3 (cg-RX-API-DMAC7.html)
ES (1) ES2718900T3 (cg-RX-API-DMAC7.html)
HU (1) HUE042271T2 (cg-RX-API-DMAC7.html)
PL (1) PL2825161T3 (cg-RX-API-DMAC7.html)
PT (1) PT2825161T (cg-RX-API-DMAC7.html)
RU (2) RU2019132222A (cg-RX-API-DMAC7.html)
TR (1) TR201904660T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013138361A1 (cg-RX-API-DMAC7.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2836216B1 (en) * 2012-04-13 2022-06-08 Epizyme, Inc. Combination therapy for treating cancer
ES2617379T3 (es) 2012-04-13 2017-06-16 Epizyme, Inc. Forma de sal de un inhibidor de histona metiltransferasa EZH2 humana
JP6254169B2 (ja) * 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
BR112015008480A2 (pt) * 2012-10-15 2017-07-04 Epizyme Inc compostos de benzeno substituído
KR20190105669A (ko) 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
PE20161273A1 (es) 2013-10-16 2016-12-18 Epizyme Inc Forma salina de hidrocloruro para la inhibicion de ezh2
WO2015058125A1 (en) * 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
MX373187B (es) 2013-12-06 2020-04-13 Epizyme Inc Terapia de combinación para tratar cáncer.
US20160361309A1 (en) * 2014-02-26 2016-12-15 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
EA038337B1 (ru) * 2014-06-17 2021-08-11 Эпизим, Инк. Ингибиторы ezh2 для лечения лимфомы
CN106795561B (zh) 2014-06-19 2021-04-16 纪念斯隆-凯特琳癌症中心 用于对ezh2抑制剂的应答的生物标志物
CN106794177A (zh) * 2014-10-16 2017-05-31 Epizyme股份有限公司 治疗癌症的方法
CA2964629A1 (en) 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
KR102964530B1 (ko) * 2014-11-17 2026-05-13 에피자임, 인코포레이티드 암을 치료하기 위한 방법
MX375970B (es) 2014-12-23 2025-03-06 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos.
WO2016172332A1 (en) * 2015-04-22 2016-10-27 The University Of North Carolina At Chapel Hill A novel compound for the treatment of ewing sarcoma and high-throughput assays for identifying small molecules that modulate aberrant chromatin accessibility
EA201890009A1 (ru) 2015-06-10 2018-07-31 Эпизайм, Инк. Ингибиторы ezh2 для лечения лимфомы
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
US20180296563A1 (en) * 2015-09-25 2018-10-18 Epizyme, Inc. Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type(sccoht) with an ezh2 inhibitor
EP3371601A1 (en) 2015-11-05 2018-09-12 Epizyme Inc Flow cytometry for monitoring histone h3 methylation status
WO2017184999A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
US10933068B2 (en) * 2016-05-26 2021-03-02 Sonic Master Limited Modulators of DUX4 for regulation of muscle function
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
US10689378B2 (en) 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
JP7042812B2 (ja) 2016-06-20 2022-03-28 ノバルティス アーゲー トリアゾロピリミジン化合物の結晶形態
WO2018075598A1 (en) 2016-10-19 2018-04-26 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
CA3044691A1 (en) 2016-10-26 2018-05-03 Genea Biocells USA (Holdings), Inc. Improved generation of muscle lineage cells and therapeutic uses thereof
EP3441388A1 (en) * 2016-11-11 2019-02-13 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. 4,5,6-tri-substituted indazoles derivatives, preparation thereof, and use thereof in medicines
CN106963765B (zh) * 2017-03-28 2020-04-07 上海交通大学医学院附属第九人民医院 Ezh2抑制剂化合物在制备治疗眼部黑色素瘤的药物中的应用
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
ES2977589T3 (es) 2017-08-18 2024-08-27 Cothera Bioscience Inc Forma polimórfica de TG02
JP7399079B2 (ja) 2017-09-05 2023-12-15 エピザイム,インコーポレイティド 癌を処置するための併用療法
WO2019204998A1 (zh) * 2018-04-25 2019-10-31 北京肿瘤医院 Ezh2抑制剂在治疗粘膜型黑色素瘤中的应用
EP3801497B1 (en) * 2018-06-03 2023-03-22 Wen-Pin Chen Method for treating non-compaction cardiomyopathy
JP7411256B2 (ja) * 2018-07-27 2024-01-11 エボポイント、バイオサイエンシズ、カンパニー、リミテッド 多置換ベンゼン環化合物、製造方法及びその用途
ES3034869T3 (en) 2019-04-22 2025-08-25 Univ Pittsburgh Commonwealth Sys Higher Education Tg02 for use in treating gliomas in pediatric subjects
CN110960525A (zh) * 2019-11-26 2020-04-07 济南大学 新型eed-ezh2相互作用抑制剂的确定和评价
CN113024516B (zh) * 2021-03-29 2022-05-17 中国药科大学 双靶点parp/ezh2抑制剂、制备方法及用途
EP4392034A1 (en) 2021-08-25 2024-07-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of ezh2 inhibitors for the treatment of aortic valve stenosis
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
CN119143880A (zh) * 2024-09-20 2024-12-17 上海交通大学医学院附属第九人民医院 抗ezh2蛋白抗体及其应用
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
JP5160885B2 (ja) 2004-06-01 2013-03-13 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 再構成ヒストンメチルトランスフェラーゼ複合体及びそのモジュレーターの識別方法
ES2324435B1 (es) * 2005-10-27 2010-05-31 Fundacion Para El Estudio De La Hematologia Y Hemoterapia De Aragon (Fehha) Procedimiento y dispositivo de analisis in vitro de mrna de genes implicados en neoplasias hematologicas.
WO2008101118A2 (en) * 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
WO2009006577A2 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
WO2009124137A2 (en) * 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
MX2012012966A (es) 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
BR112013005806B1 (pt) * 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
JO3363B1 (ar) * 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9730925B2 (en) * 2011-09-30 2017-08-15 Glaxomithkline Llc Methods of treating cancer

Similar Documents

Publication Publication Date Title
JP2015511603A5 (cg-RX-API-DMAC7.html)
RU2014141045A (ru) Ингибиторы ezh2 человека и способы их применения
Van der Jeught et al. Drug resistance and new therapies in colorectal cancer
JP7504853B2 (ja) 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド
Guasp et al. The Behçet's disease-associated variant of the aminopeptidase ERAP1 shapes a low-affinity HLA-B* 51 peptidome by differential subpeptidome processing
JP2018529698A5 (cg-RX-API-DMAC7.html)
US20130195843A1 (en) Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof
JP2016026215A5 (cg-RX-API-DMAC7.html)
RU2018145311A (ru) Способы лечения рака
JP2013518055A5 (cg-RX-API-DMAC7.html)
IL273254B1 (en) HLA type II-restricted T cell receptors against RAS
JP2015525208A5 (cg-RX-API-DMAC7.html)
JP2016532693A5 (cg-RX-API-DMAC7.html)
KR20170090447A (ko) 간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
JP2016513104A5 (cg-RX-API-DMAC7.html)
RU2016124179A (ru) СКОНСТРУИРОВАННЫЕ ВЫСОКОАФФИННЫЕ T-клеточные рецепторы человека
SI3079715T1 (en) A mixture of peptides
JP2019501920A5 (cg-RX-API-DMAC7.html)
Vauchy et al. CD20 alternative splicing isoform generates immunogenic CD 4 helper T epitopes
FI3448879T3 (fi) Claudin-6 -peptidejä
Misra et al. Role of cytokines in combinatorial immunotherapeutics of non‐small cell lung cancer through systems perspective
Lin et al. Decoding MHC loss: Molecular mechanisms and implications for immune resistance in cancer
Than et al. KRAS-driven tumorigenesis and KRAS-driven therapy in pancreatic adenocarcinoma
US20230002490A1 (en) Determinants of cancer response to immunotherapy
Chen-Camaño et al. T-cell exhaustion in COVID-19: what do we know?